Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year

Guidi, L.; Marzo, Manuela; Andrisani, Gianluca; Felice, Carla; Pugliese, Daniela; Mocci, Giammarco; Nardone, Olga Maria; Vitis, I. De; Papa, Alfredo; Rapaccini, G.L.; Forni, Floreal H.; Armuzzi, Alessandro

doi:10.1016/j.dld.2014.07.013

Cited by 73 publications

(62 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fecal calprotectin concentrations were numerically higher in SRE/IRE dogs with PR/NR compared to those dogs with CR, but significance was not reached likely because of the low statistical power. Higher pretreatment fecal calprotectin concentrations in SRE/IRE dogs with only partial or no response to treatment (PR/NR) is consistent with the results of studies in children and human adults with IBD showing lower fecal calprotectin concentrations to predict clinical remission or to predict sustained clinical remission over 1 year . This finding also agrees with the results for fecal S100A12 in dogs with CIE where fecal S100A12 concentrations ≥2,700 ng/g identified dogs with IBD that were refractory to anti‐inflammatory/immunosuppressive treatment .…”

Section: Discussionsupporting

confidence: 87%

Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies

Heilmann

Berghoff

Mansell

et al. 2018

Veterinary Internal Medicne

107

View full text Add to dashboard Cite

BackgroundCalprotectin is a marker of inflammation, but its clinical utility in dogs with chronic inflammatory enteropathies (CIE) is unknown.ObjectiveEvaluation of fecal calprotectin in dogs with biopsy‐confirmed CIE.Animals127 dogs.MethodsProspective case‐control study. Dogs were assigned a canine chronic enteropathy clinical activity index (CCECAI) score, and histologic lesions severity was assessed. Fecal calprotectin, fecal S100A12, and serum C‐reactive protein (CRP) were measured. Food‐ or antibiotic‐responsive cases (FRE/ARE, n = 13) were distinguished from steroid‐/immunosuppressant‐responsive or ‐refractory cases (SRE/IRE, n = 20). Clinical response to treatment in SRE/IRE dogs was classified as complete remission (CR), partial response (PR), or no response (NR).ResultsFecal calprotectin correlated with CCECAI (ρ = 0.27, P = .0065) and fecal S100A12 (ρ = 0.90, P < .0001), some inflammatory criteria, and cumulative inflammation scores, but not serum CRP (ρ = 0.16, P = .12). Dogs with SRE/IRE had higher fecal calprotectin concentrations (median: 2.0 μg/g) than FRE/ARE dogs (median: 1.4 μg/g), and within the SRE/IRE group, dogs with PR/NR had higher fecal calprotectin (median: 37.0 μg/g) than dogs with CR (median: 1.6 μg/g). However, both differences did not reach statistical significance (both P = .10). A fecal calprotectin ≥15.2 μg/g separated both groups with 80% sensitivity (95% confidence interval [95%CI]: 28%‐100%) and 75% specificity (95%CI: 43%‐95%).Conclusions and Clinical ImportanceFecal calprotectin could be a useful surrogate marker of disease severity in dogs with CIE, but larger longitudinal studies are needed to evaluate its utility in predicting the response to treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies

Heilmann

Berghoff

Mansell

et al. 2018

Veterinary Internal Medicne

107

View full text Add to dashboard Cite

show abstract

“…C‐reactive protein and fecal calprotectin are not a target in IBD treatment but may guide objective assessment of disease activity. The normalization of C‐reactive protein and/or fecal calprotectin at weeks 10–14 of treatment is associated with improved outcomes of clinical remission and mucosal healing in CD and UC . Cross‐sectional imaging, to date, is not formally considered treatment target in UC but play a role in the assessment of CD lesions beyond the reach of endoscopy …”

Section: Resultsmentioning

confidence: 99%

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi

Hilmi

Banerjee

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all‐encompassing, and future revisions are likely as new data continue to emerge.

show abstract

“…The GS findings, on the other hand, represent synovium that may be more or less actively inflamed and may therefore not have the same association with inflammatory markers. As a parallel, in inflammatory bowel diseases, calprotectin levels (in faeces) have been shown to be associated with inflammation and found to be highly useful in the clinics by predicting clinical response and mucosal healing in patients treated with biologics [45]. …”

Section: Discussionmentioning

confidence: 99%

Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis

et al. 2017

View full text Add to dashboard Cite

BackgroundCalprotectin (S100A8/A9 or MRP8/14) and S100A12 (leukocyte-derived proteins), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) are markers of inflammation and angiogenesis. Ultrasound (US) is sensitive for detection of greyscale synovitis and power Doppler (PD) vascularization. The objective of the present study was to explore the associations between calprotectin, S100A12, IL-6, VEGF, erythrocyte sedimentation rate, C-reactive protein and a comprehensive US assessment in patients with rheumatoid arthritis (RA) starting biologic disease-modifying anti-rheumatic drug (bDMARD) treatment.MethodsA total of 141 patients with RA were assessed by US, clinical examination and biomarker levels at baseline and at 1, 2, 3, 6 and 12 months after initiation of bDMARDs. US assessment of 36 joints and 4 tendon sheaths were scored semi-quantitatively (0–3 scale). European League Against Rheumatism (EULAR) response was calculated. Statistical assessments performed to explore the associations between biomarkers and US sum scores included Spearman’s rank correlation analysis as well as linear and linear mixed model regression analyses.ResultsCalprotectin showed the overall strongest correlations with both US sum scores (r s = 0.25–0.62) and swollen joint counts (of 32) (r s = 0.24–0.47) (p < 0.05 at all examinations). An association with US sum scores remained after we adjusted for age, sex, disease duration and all the other markers in a regression analysis at baseline. Decreased calprotectin at the first month was predictive of both EULAR response (p ≤ 0.001) and decreased sum PD scores at 3, 6 and 12 months (p ≤ 0.05).ConclusionsCalprotectin had the highest association with US synovitis and predicted treatment response. It may thus be considered as a marker for evaluating inflammation and responsiveness in patients with RA on bDMARD treatment.Trial registrationAustralian New Zealand Clinical Trials Registry (ANZCTR) identifier: ACTRN12610000284066. Registered on 8 April 2010 (retrospectively registered).Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-016-1201-0) contains supplementary material, which is available to authorized users.

show abstract

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year

Cited by 73 publications

References 28 publications

Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies

Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis

Contact Info

Product

Resources

About